Please login to the form below

Not currently logged in
Email:
Password:

MorphoSys appoints Dr Markus Enzelberger as CSO

He succeeds Dr Marlies Sproll who resigns

Markus EnzelbergerGerman biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation.

Sproll will remain with the company on a part-time basis as a special advisor to chief executive officer Dr Simon Moroney, however Dr Enzelberger, who joined MorphySys in 2002, has served as its interim CSO since April this year.

Dr Enzelberger has served in various capacities at MorphoSys including senior vice president, discovery, alliances and technologies, taking responsibility for the drug discovery activities for proprietary and partnered programmes.

Dr Gerald Moller, supervisory board chairman, MorphoSys, said: “Dr Enzelberger is the perfect person to take over the CSO role at MorphoSys on a permanent basis.

“Drawing on his vast scientific expertise and experience in the management of antibody technology, research and discovery, he will continue to drive the group’s early-stage research activities with the goal of fuelling the company’s R&D pipeline with novel drug candidates in oncology and immunology.”

9th November 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....
Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...

Infographics